Serological survey


Last updated: 2021 Jun 14
Total hit(s): 29
Select item(s)
Key Findings
Comments
(You can add your comments too!)
Original Article
(hover to see details)
In 19205 participants, the seroprevalence was <3% until Mid-December 2020 in all regions. Mostly low seroprevalence was estimated in Reutlingen, Aachen, Freiburg, and Osnabrück after the first wave while serological study in Magdeburg cumulatively already indicates the onset of the second wave. Unweighted and weighted SARS-CoV-2 seroprevalences for all study population: Table 5 (https://www.medrxiv.org/content/medrxiv/early/2021/05/06/2021.05.04.21256597/T5/graphic-12.large.jpg and https://www.medrxiv.org/content/medrxiv/early/2021/05/06/2021.05.04.21256597/T5/graphic-13.large.jpg)
Pre-print (bioRXiv)
Date of Publishing 2021 May 6
Title SARS-CoV-2 seroprevalence in Germany - a population based sequential study in five regions
Author(s) name Manuela Harries
Date of Entry 2021 Jun 14


Serological survey of mild/asymptomatic SARS-CoV-2 infected individuals were tested with three immunoassays. Antibodies were found to be present for atleast 8 months after infection. No comments
Pre-print (medRXiv)
Date of Publishing -
Title Serological survey of mild/asymptomatic SARS-CoV-2 infected individuals were tested with three immunoassays. Antibodies were found to be present for atleast 8 months after infection.
Author(s) name -
Date of Entry 2021 Jun 14


Serological survey of mild/asymptomatic SARS-CoV-2 infected individuals were tested with three immunoassays. Antibodies were found to be present for atleast 8 months after infection. No comments
Pre-print (medRXiv)
Date of Publishing -
Title Persistence and detection of anti-SARS-CoV-2 antibodies: immunoassay heterogeneity and implications for serosurveillance
Author(s) name -
Date of Entry 2021 Jun 14


Out of 30 COVID-S*19 patients, 23 showed the presence of anti-S*N antibodies, 20 showed anti-S*** antibodies, and 13 had anti-S*M antibodies. S** corresponds to full-length spike that carries a pair of trimer-stabilizing proline mutations (986KV987 to 986PP987) and a quartet of substitutions at the S1/S2 protease cleavage site (682RRAR685 to 682GSAG685)
33330866
(bioRxiv)
PMID
33330866
Date of Publishing: 2020 Dec 9
Title The D614G Mutation Enhances the Lysosomal Trafficking of SARS-CoV-2 Spike
Author(s) nameGuo C, Tsai SJ et al.
Journal bioRxiv
Impact factor
Its not a journal
Citation count: 1


Out of 10,449 Healthcare professionals, 136 showed seropositivity with 70% presenting with symptoms, including Cough (23.2%), Headache (22.1%) and Fatigue (21.1%).
33292895
(Infect Control Hosp Epidemiol)
PMID
33292895
Date of Publishing: 2020 Dec 9
Title Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence in healthcare personnel in northern California early in the coronavirus disease 2019 (COVID-19) pandemic
Author(s) nameRosser JI, Röltgen K et al.
Journal Infect Control Hosp Epidemiol
Impact factor
2.66
Citation count: 1


Out of 1686 individuals in Germany, 46 (2.7%) were seropositive for anti-SARS-CoV-2 IgG antibodies.
33339986
(Nat Rev Rheumatol)
PMID
33339986
Date of Publishing: 2020 Dec 18
Title Rheumatic disease and COVID-19: epidemiology and outcomes
Author(s) name Hyrich KL, Machado PM.
Journal Nat Rev Rheumatol
Citation count 2


Out of 790 participants in an University student population, estimated seroprevalence of Anti-SARS-CoV-2 IgG antibodies was 4%. This indicated that the prevalence of infection/SARS-COV-2 antibodies in a University population was similar to the community seroprevalence.
33071164
(J Adolesc Health)
PMID
33071164
Date of Publishing: 2020 Dec
Title A Cross-Sectional Study Examining the Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies in a University Student Population
Author(s) nameTilley K, Ayvazyan V et al.
Journal J Adolesc Health
Impact factor
6.3
Citation count: 1


Out of 7361 individuals in Netherlands, 200 (2.7%) were seropositive. Antibodies were more significantly detected in younger people of 18-30 years age group (4.2%) compared to older people of 61-72 years age group (2.7%).
33184284
(Nat Commun)
PMID
33184284
Date of Publishing: 2020 Nov 12
Title Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands
Author(s) nameSlot E, Hogema BM et al.
Journal Nat Commun
Impact factor
11.8
Citation count: 2


Out of 1122 participants in an Indian Tertiary care hospital, overall seroprevalence for SARS-CoV-2 IgG antibodies was 11.94% of which 19.85% of High risk healthcare workers, 11.09% of Intermediate risk Healthcare workers and 8% of Low risk healthcare workers were seropositive .
33187030
(J Assoc Physicians India)
PMID
33187030
Date of Publishing: 2020 Nov
Title Seroprevalence of COVID-19 amongst Health care workers in a Tertiary Care Hospital of a Metropolitan City from India
Author(s) nameGoenka M, Afzalpurkar S et al.
Journal J Assoc Physicians India
Impact factor
0.5
Citation count: 2


Among the healthworkers under study, majority were seronegative indicating lack of antibodies to SARS-CoV-2.
33033249
(Nat Commun)
PMID
33033249
Date of Publishing: 2020 Oct 8
Title SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden
Author(s) nameRudberg AS, Havervall S et al.
Journal Nat Commun
Impact factor
11.8
Citation count: 11


Out of 1215 recovered persons and 4222 quarantined persons,1107 (91.1%) and 97 (2.3%) were seropositive, respectively.
32871063
(N Engl J Med)
PMID
32871063
Date of Publishing: 2020 Oct 29
Title Humoral Immune Response to SARS-CoV-2 in Iceland
Author(s) nameGudbjartsson DF, Norddahl GL et al.
Journal N Engl J Med
Impact factor
37.91
Citation count: 80


Seroconversion of SARS-CoV-2 in people living with HIV (PLWH) on stable ART occurred similarly to that in non-HIV-infected patients.
33046418
(J Microbiol Immunol Infect)
PMID
33046418
Date of Publishing: 2020 Oct 2
Title Antibody response to SARS-CoV-2 in people living with HIV.
Author(s) nameYamamoto S, Saito M et al.
Journal J Microbiol Immunol Infect
Impact factor
2.33
Citation count: 1


Out of 291 participants in long term facilities, including 122 residents and 169 staff, 113 were sero-reactive and 178 were non-reactive.
33086096
(Am J Infect Control)
PMID
33086096
Date of Publishing: 2020 Oct 18
Title Serological survey following SARS-COV-2 outbreaks at long term care facilities in netro Vancouver, British Columbia: Implications for outbreak management and infection control policies
Author(s) nameVijh R, Ghafari C et al.
Journal Am J Infect Control
Impact factor
2.03
Citation count: 1


Out of 5391 participants, a seropositivity rate of 61.2% for IgM, 58.8% for IgG and 62.1% for IgM/IgG in COVID-19 confirmed cases, seropositivity rate of 29% for IgM, 37% for IgG, 55% for both IgM/IgG in suspected cases and 19% for IgM/IgG in asymptomatic cases were observed.
33090430
(Eur Rev Med Pharmacol Sci)
PMID
33090430
Date of Publishing: 2020 Oct
Title Seropositivity rate and diagnostic accuracy of serological tests in 2019-nCoV cases: a pooled analysis of individual studies
Author(s) name Guo CC, Mi JQ, Nie H.
Journal Eur Rev Med Pharmacol Sci
Impact factor
2.51
Citation count: 1


Out of 464 healthcare workers, 809 industrial employees and 402 community members in Karachi, Pakistan, 13%, 50.3% and 34%, were seropositive respectively. Overall seroprevalence rate was 36%.
32940328
(J Public Health (Oxf))
PMID
32940328
Date of Publishing: 2020 Sep 17
Title Seroprevalence of anti-SARS-CoV-2 antibodies in residents of Karachi - Challenges in acquiring herd immunity for COVID-19
Author(s) nameZaidi S, Rizwan F et al.
Journal J Public Health (Oxf)
Impact factor
1.55
Citation count: 1


Out of 51958 participants in Spain, overall seroprevalence rate was 4.6% using Chemiluminescence immunoassay. Out of 4.6%, patients with positive PCR status greater than 14 days showed 90.1% seroprevalence rate.
32645347
(Lancet)
PMID
32645347
Date of Publishing: 2020 Aug 22
Title Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study.
Author(s) namePollán M, Pérez-Gómez B et al.
Journal Lancet
Impact factor
43.38
Citation count: 198


Out of 61075 participants in Spain, overall seroprevalence rate was 5% using Point rapid care testing. Out of 5% ,patients with positive PCR status greater than 14 days showed 88.6% seroprevalence rate.
32645347
(Lancet)
PMID
32645347
Date of Publishing: 2020 Aug 22
Title Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study.
Author(s) namePollán M, Pérez-Gómez B et al.
Journal Lancet
Impact factor
43.38
Citation count: 198


Seroprevalence estimates for 5 weeks did not show much difference after 1st week of the study.
32534626
(Lancet)
PMID
32534626
Date of Publishing: 2020 Aug 1
Title Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study
Author(s) nameStringhini S, Wisniak A et al.
Journal Lancet
Impact factor
43.38
Citation count: 119


Out of 17368 participants, cumulative seroprevalence of IgM and IgG was reported as 44% and 56%, respectively.
32504052
(Nat Med)
PMID
32504052
Date of Publishing: 2020 Aug
Title Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China
Author(s) nameXu X, Sun J et al.
Journal Nat Med
Impact factor
22.66
Citation count: 48


Out of 1293 parturient women in Philadelphia, 80 (6.2%) had IgG and/or IgM SARS-CoV-2specific antibodies. The seropositivity was higher in Black/non-Hispanic and Hispanic/Latino women compared to Asian and White/non-Hispanic women.
32727884
(Sci Immunol)
PMID
32727884
Date of Publishing: 2020 Jul 29
Title SARS-CoV-2 seroprevalence among parturient women in Philadelphia
Author(s) nameFlannery DD, Gouma S et al.
Journal Sci Immunol
Impact factor
8.16
Citation count: 19


Out of 1914 serum samples from 35 species of animals, none of them were seropositive.
32303108
(Transbound Emerg Dis)
PMID
32303108
Date of Publishing: 2020 Jul
Title Serological survey of SARS-CoV-2 for experimental, domestic, companion and wild animals excludes intermediate hosts of 35 different species of animals
Author(s) nameDeng J, Jin Y et al.
Journal Transbound Emerg Dis
Impact factor
3.47
Citation count: 23


Out of 1071 samples, 41 samples were SARS-CoV-2 IgG positive with a proportion of 3.83%, including 4.8% in central metropolitan Tokyo, 1.6% in suburban Tokyo and the highest 7.92% in the southern areas of central Tokyo.
32674696
(J Prim Care Community Health)
PMID
32674696
Date of Publishing: 2020 Jan-Dec
Title Geographical Profiles of COVID-19 Outbreak in Tokyo: An Analysis of the Primary Care ClinicBased Point-of-Care Antibody Testing
Author(s) nameTakita M, Matsumura T et al.
Journal J Prim Care Community Health
Impact factor
1.4
Citation count: 3


Out of 1071 patient samples in Tokyo, 41 (3.83%) samples were SARS-CoV-2 IgG positive including a seroprevalence rate of 4.8% in Central metropolitan Tokyo, 1.6% in suburban Tokyo and the highest rate of 7.92% in the southern areas of central Tokyo.
32674696
(J Prim Care Community Health)
PMID
32674696
Date of Publishing: 2020 Jan-Dec
Title Geographical Profiles of COVID-19 Outbreak in Tokyo: An Analysis of the Primary Care Clinic-Based Point-of-Care Antibody Testing
Author(s) nameTakita M, Matsumura T et al.
Journal J Prim Care Community Health
Impact factor
1.4
Citation count: 3


Out of 200 children in Prague, 2 were seropositive (<0.5%) which was comparatively lesser than overall seroprevalence (1.3%). Median age of the children in the study was 9 years.
33304869
(Front Pediatr)
PMID
33304869
Date of Publishing: 2020
Title Searching for COVID-19 Antibodies in Czech ChildrenA Needle in the Haystack
Author(s) nameBloomfield M, Pospisilova I et al.
Journal Front Pediatr
Impact factor
2.46
Citation count: 1


Out of 2906 individuals tested for SARS-CoV-2 IgG antibodies, 111 (3.8%) were seropositive. 14 (10.4%) out of 135 symptomatic and 97 (3.5%) out of 2771 asymptomatic patients were IgG seropositive.
33175878
(PLoS One)
PMID
33175878
Date of Publishing: 2020
Title Seroprevalence of SARS-CoV-2 specific IgG antibodies in District Srinagar, northern India - A cross- sectional study
Author(s) nameKhan SMS, Qurieshi MA et al.
Journal PLoS One
Impact factor
2.87
Citation count: 1